Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bisoprolol is a highly selective β1-adrenergic receptor blocker (beta-blocker) used primarily for the treatment of hypertension, angina pectoris (coronary heart disease/angina), certain arrhythmias (such as rapid supraventricular arrhythmias and ventricular premature beats), and chronic stable heart failure with reduced ejection fraction. It has no intrinsic sympathomimetic activity or membrane-stabilizing effect. Bisoprolol exhibits a high affinity for β1 receptors—11 to 34 times greater than for β2 receptors—and its selectivity is about four times that of atenolol. The drug has a long duration of action (>24 hours), minimal respiratory side effects at therapeutic doses, and does not significantly affect lipid metabolism. It is well absorbed orally with high bioavailability (~90%), low first-pass effect (<10%), peak plasma concentration in 1.7–3 hours, and an elimination half-life of about 10 hours[2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bisoprolol.